Development of an immuno-mass spectrometric assay for validation of protein C inhibitor (PCI) as a biomarker for prediction of biochemical recurrence in prostate cancer patients
Biomarker validation remains one of the most important constraints to development of new clinical diagnostic assays. To address this challenge, an immuno-mass spectrometric assay known as SISCAPA has been developed for quantitation of protein biomarkers in human blood. The SISCAPA assay overcomes...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | English en |
| Published: |
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1828/4375 |